CAMBRIDGE, Mass., Feb. 29, 2016 /CNW/ -- Spero Therapeutics, a biopharmaceutical company founded to develop novel therapies to treat bacterial infections, announced today that Ankit Mahadevia, President and CEO, will present a company overview at the Cowen and Company 36th Annual Health Care Conference on Monday, March 7, 2016 at 12:00 p.m. ET in Boston, MA.
Spero is a biopharmaceutical company developing a pipeline of novel treatments for bacterial infections and is located in Cambridge, Massachusetts. The company's pipeline of anti-infective agents is one of the most unique in the industry – focused on serious Gram-negative bacterial infections for which a high unmet need exists for new therapies. Spero is pioneering an entirely new therapeutic platform called the Potentiator that enhances the utility and potency of many classes of existing drugs to include coverage of multi drug-resistant Gram-negative organisms affecting hospitalized patients.
Spero's DHFR program is exploring the expansion of a novel antifolate's antibacterial spectrum to treat trimethoprim resistant isolates including Gram-negative pathogens. The program has IV and Oral bioavailability enabling treatment of drug resistant infections in a step down and community setting. Spero's MvfR program is exploring the hypothesis of blunting the virulence of bugs, infections, essentially "buying time" so antibiotics can take effect. The investors in Spero include Atlas Ventures, SR One, MRL Ventures Lundbeckfond Ventures, The Kraft Group, and The Partners Innovation Fund. For more information, please visit www.sperotherapeutics.com
SOURCE Spero Therapeutics
For further information: Spectrum Science Communications: Maia Arnold, PhD, Senior Scientific Executive, 202-955-6222 x2506, email@example.com; INVESTOR CONTACT: Stern Investor Relations, Beth DelGiacco, Vice President, 212-362-1200, Beth@sternir.com, http://www.sperotherapeutics.com/